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Dear Editor
Proteins of the peroxisome proliferator-activated receptor γ coactivator 1 (PGC1) family are 
transcriptional coactivators well known for regulating mitochondrial biogenesis and other 
metabolic functions in multiple tissues 1. Recently, PGC1 coactivators have also been linked 
to pigmentation and melanoma skin cancer. In a genome-wide association study 2, our group 
determined the A allele of SNP rs32579 in the PGC1β gene was significantly associated 
with greater tanning ability, which was successfully replicated in additional samples 3. 
Furthermore, we demonstrated that the rs32579 A allele was correlated with upregulation of 
PGC1β gene expression and lower risk of melanoma 3. However, whether this SNP 
influences risk of melanoma death remains a question of interest.
We thus investigated the association between the genetic variant rs32579 A and melanoma 
mortality among 858 melanoma cases. All patients were accrued from a hospital-based case-
control study of melanoma skin cancer at The University of Texas MD Anderson Cancer 
Center (MDACC). Melanoma-specific death was the primary endpoint of the current 
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analysis. We calculated survival time from the date of diagnosis to the date of death from 
melanoma or the date of the last follow-up, whichever came first. Multivariate Cox 
proportional hazards regression models, adjusted for age, sex, tumor stage, Breslow 
thickness, tumor cell mitotic rate, and top two principal components of genetic variance, 
were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for the 
association between rs32579 and melanoma mortality. Our result showed that A allele was 
associated with a lower risk of melanoma disease-specific death (Table 1, HR=0.64, 95% 
CI=0.45–0.91, p-value=0.013). Previously, the telomere-mitochondrion connection was 
shown to be regulated by PGC1s 4, and telomere length was positively correlated with nevus 
count 5. We therefore further examined the possible association between this variant and 
nevus count, a well-known risk factor for malignant melanoma. Among 15,952 individuals 
of European Ancestry in the Nurses’ Health Study (NHS) and the Health Professionals 
Follow-up Study (HPFS), the number of nevi decreases by 0.06 per each A allele (p-
value=0.018). Detailed methods of this additional analysis on nevus count have been 
described previously 6. Information on study population, genotyping procedure, quality 
control and imputation are provided in Supplementary Materials, for the MDACC study, the 
NHS and the HPFS.
PGC1 β and PGC1 α normally co-express with each other, and they share a large degree of 
sequence homology and functional overlap 1. PGC1α-positive melanomas have been found 
to have higher rates of survival under oxidative stress compared to PGC1α-negative 
melanoma 7. Last year, Luo et al. reported that PGC1α suppressed melanoma metastasis 
through direct regulation of parallel-acting transcriptional programs 8. Though not on PGC1 
β, these findings may support our observations in the current population study.
In summary, we so far have shown that this SNP was associated with tanning ability, nevus 
count, and both melanoma risk and mortality, which further emphasizes the critical role of 
PGC1s in multiple steps of melanocyte formation and melanoma development. BRAF 
inhibition regulates PGC1α expression in BRAF-mutated melanoma, which affects the 
therapeutic efficacy of BRAF inhibitors 9. Future studies are warranted to investigate the 
effect modification of this PGC1β variant on BRAF inhibitors in melanoma treatment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Association between PGC1β rs32579 # and melanoma-specific death
Genotype No. of patients No. of deaths HR (95%CI) * P-value
GG 454 56 1.00 (Ref)
GA 331 34 0.62 (0.40–0.97)
AA 73 5 0.44 (0.17–1.10)
Additive model (G – ref allele, A – test allele) 0.64 (0.45–0.91) 0.013
#SNP rs32579 is located on chromosome 5 with BP position at 149210848. The G allele is the major allele, and the A allele is the minor allele. 
Minor allele frequency = 0.28.
*Cox proportional hazards regression model, adjusted for age, sex, tumor stage, Breslow thickness, tumor cell mitotic rate, and the top two 
principal components.
Int J Cancer. Author manuscript; available in PMC 2018 September 01.
